Aethlon Medical, Inc. (AEMD) Bundle
An Overview of Aethlon Medical, Inc. (AEMD)
General Summary of Aethlon Medical, Inc. (AEMD)
Aethlon Medical, Inc. is a medical technology company focused on developing therapeutic technologies targeting infectious diseases and cancer. The company's primary product is the Hemopurifier, a medical device designed for blood filtration.
| Company Detail | Specific Information |
|---|---|
| Headquarters | San Diego, California |
| Founded | 1992 |
| Stock Exchange | NASDAQ |
| Ticker Symbol | AEMD |
Company Financial Performance
For the fiscal year 2023, Aethlon Medical reported the following financial metrics:
| Financial Metric | Amount |
|---|---|
| Total Revenue | $3.2 million |
| Net Loss | $14.6 million |
| Cash and Cash Equivalents | $7.9 million |
Key Product and Technology Focus
- Hemopurifier technology for viral and cancer treatment
- Advanced blood filtration systems
- Research in immunotherapy applications
Industry Leadership Highlights
Unique Technology Positioning: Aethlon Medical specializes in developing innovative therapeutic technologies for complex medical challenges, particularly in infectious disease and oncology treatment.
| Technology Area | Current Development Stage |
|---|---|
| Hemopurifier Platform | Advanced clinical research stage |
| Cancer Treatment Applications | Ongoing clinical trials |
| Infectious Disease Filtration | Investigational development |
The company continues to focus on advancing its proprietary Hemopurifier technology across multiple therapeutic domains.
Mission Statement of Aethlon Medical, Inc. (AEMD)
Mission Statement of Aethlon Medical, Inc. (AEMD)
Aethlon Medical, Inc. focuses on developing medical technologies targeting cancer, infectious diseases, and inflammatory conditions.
Core Mission Components
| Technology Focus | Hemopurification and immunotherapy platforms |
| Primary Research Area | Extracorporeal blood filtration technologies |
| Key Target Diseases | Cancer, viral infections, inflammatory conditions |
Strategic Technology Development
Aethlon Medical's mission centers on developing the Aethlon Hemopurification Platform, specifically the Hemopurifier device.
- Total R&D Investment in 2023: $3.2 million
- Patent Portfolio: 17 active patents
- Clinical Stage Technologies: 2 primary platforms
Technological Innovation Metrics
| Research Budget | $3,200,000 |
| Active Clinical Trials | 3 |
| Technology Development Timeline | 10-15 years continuous research |
Market Positioning
Specialized medical technology development with focus on advanced hemopurification solutions.
- Market Capitalization: $24.5 million
- Annual Revenue: $1.8 million
- Employee Count: 32 professionals
Vision Statement of Aethlon Medical, Inc. (AEMD)
Vision Statement of Aethlon Medical, Inc. (AEMD)
Strategic Vision for Medical InnovationAethlon Medical's vision focuses on advancing medical technology through targeted therapeutic approaches, specifically in the areas of immunotherapy and extracellular vesicle (EV) engineering.
Key Vision Components| Primary Focus Area | Immunotherapeutic Technologies |
| Target Market | Oncology and Infectious Disease Treatment |
| Research Investment (2023) | $3.2 million |
| Patent Portfolio | 12 active patents |
- Develop Hemopurifier® platform for selective therapeutic filtration
- Advance exosome detection and manipulation technologies
- Create targeted immunomodulation solutions
| R&D Expenditure Percentage | 62% of total operational budget |
| Clinical Trial Stages | 2 ongoing Phase II trials |
| Technology Readiness Level | Level 6-7 in key therapeutic platforms |
Aethlon Medical aims to position itself as a pioneering biotechnology company specializing in advanced therapeutic filtration and immunoengineering technologies.
Core Values of Aethlon Medical, Inc. (AEMD)
Core Values of Aethlon Medical, Inc. (AEMD) in 2024
Innovation and Scientific Excellence
As of Q1 2024, Aethlon Medical demonstrates commitment to innovation through:
- 3 active patent applications in immunotherapy technologies
- R&D investment of $4.2 million in fiscal year 2023
- Ongoing development of Hemopurifier® platform technology
| R&D Metric | 2024 Value |
|---|---|
| Annual R&D Expenditure | $4,200,000 |
| Active Research Projects | 5 |
Patient-Centric Approach
Clinical focus areas in 2024:
- Cancer immunotherapy research
- Infectious disease treatment development
- Ongoing clinical trials in metastatic cancer
| Clinical Trial Status | 2024 Details |
|---|---|
| Active Clinical Trials | 2 |
| Patient Enrollment | 47 participants |
Ethical and Transparent Operations
Compliance and governance metrics for 2024:
- 100% regulatory compliance with FDA guidelines
- Independent board oversight
- Quarterly financial reporting transparency
| Governance Metric | 2024 Value |
|---|---|
| Independent Board Members | 4 out of 6 |
| Audit Committee Meetings | 4 per year |
Collaborative Research Commitment
Research collaboration metrics in 2024:
- 3 active academic research partnerships
- 2 pharmaceutical industry collaborations
- Total collaboration investment: $1.5 million
| Collaboration Type | Number in 2024 |
|---|---|
| Academic Partnerships | 3 |
| Industry Collaborations | 2 |
Aethlon Medical, Inc. (AEMD) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.